Earnings Analysis Dashboard – JBCHEPHARM
Structured AI analysis of company financial results designed to help traders and investors quickly understand key performance trends.
Type of Announcement
The Board of Directors of J.B. Chemicals & Pharmaceuticals Ltd. has announced the audited consolidated financial results for the quarter and year ended March 31, 2026.
Revenue
₹4,147.79 Crs.
▲ +5.0% QoQ
Net Profit
₹101.37 Crs.
▲ +1.7% YoY
Key Financial Numbers (Quarter)
| Metric |
Current Quarter (Mar 2026) |
Previous Quarter (Dec 2025) |
Same Quarter Last Year (Mar 2025) |
| Revenue (₹ Crs.) |
₹4,147.79 |
₹4,145.79 |
₹4,094.55 |
| Net Profit (₹ Crs.) |
₹101.37 |
₹197.89 |
₹145.69 |
| EPS |
6.35 |
12.63 |
9.36 |
| EBITDA Margin (%) |
N/A |
N/A |
N/A |
What EPS Means
EPS (Earnings Per Share) shows how much profit a company generates for each share.
Higher EPS usually indicates stronger profitability and better earnings power for shareholders.
What EBITDA Margin Means
EBITDA Margin measures operating profitability before interest, tax, depreciation and amortization.
A higher margin suggests the company is generating stronger operating profits from its revenue.
Revenue Trend
Mar 2026
₹4,147.79 Crs.
Dec 2025
₹4,145.79 Crs.
Mar 2025
₹4,094.55 Crs.
Profit Trend
Mar 2026
₹101.37 Crs.
Dec 2025
₹197.89 Crs.
Mar 2025
₹145.69 Crs.
Quick Interpretation
- QoQ revenue trend:
Strong recovery (+5.0%)
- YoY revenue trend:
Slight increase (+1.3%)
- QoQ profit trend:
Significant decline (-48.8%)
- YoY profit trend:
Improved slightly (+1.7%)
Major Corporate Events
- Board has recommended a final dividend of ₹9.30 per equity share.
Trading Signals
- Positive Factors: Proposed merger with Torrent Pharmaceuticals
- Negative Factors: EBITDA margin details not available
Overall Sentiment
Neutral
Disclaimer
This report has been analysed and generated using AI based on publicly available corporate announcements and financial disclosures published by the company on NSE INDIA Website.
We are not registered with SEBI as an investment advisor or research analyst. This report is provided strictly for informational and educational purposes only.
Investors should not treat this analysis as financial advice, stock recommendation, or investment guidance. Always conduct your own research or consult a SEBI-registered financial advisor before making investment decisions.
The platform does not guarantee accuracy, completeness, or timeliness of the extracted information.